Nicola Tolliday, Ph.D.
Nicola Tolliday serves as the director of operations for the Broad Institute’s Center for the Development of Therapeutics (CDoT), and she is the alliance manager for the Broad/Bayer Healthcare oncology collaboration.
Previously, Tolliday was part of the leadership group that advanced MCL1, ERG, MUC1, PCSK9, and FadD32 as institutional therapeutics projects. She also established and led the high-throughput screening group within the Broad Institute’s Therapeutics Platform from 2004 to 2009. Additionally, Tolliday established the Chemical Biology Outreach Lab to support collaborators with assay development expertise, automation facilities for pilot screening, and follow-on studies for chemical biology projects within the Broad Institute discovery pipeline.
Prior to joining the Broad Institute, Tolliday was a senior assay developer at the Harvard Institute of Chemistry and Cell Biology, where she was responsible for the development, execution, and analysis of high-throughput small-molecule screens, in particular those with relevance to cancer biology. In addition, she advised and collaborated with researchers nationwide on the design and implementation of successful high-throughput screens.
Tolliday received her B.S. from the University of Bath, England, in biochemistry, during which time she completed internships at the Weizmann Institute, Israel, and the Max Planck Institute for Biochemistry, Germany. She received her Ph.D. from Harvard University in cell biology.